Filing Details

Accession Number:
0001209191-19-047753
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-29 18:26:54
Reporting Period:
2019-08-28
Accepted Time:
2019-08-29 18:26:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1728117 Gossamer Bio Inc. GOSS Pharmaceutical Preparations (2834) 475461709
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1766404 Luisa Salter-Cid 3013 Science Park Road
San Diego CA 92121
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-08-28 23,748 $19.65 150,308 No 4 S Direct
Common Stock Disposition 2019-08-29 26,252 $20.09 124,056 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.50 to $19.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. Includes 97,908 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 20, 2021, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. The shares are also subject to certain accelerated vesting provisions as set forth in more detail in the employment agreement between the Issuer and the Reporting Person.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.71 to $20.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.